Mechanisms of motor superperformance
运动超性能的机制
基本信息
- 批准号:10701427
- 负责人:
- 金额:$ 53.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-21 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AdenovirusesAnimalsBehavioralBindingBiological AssayBrainCellsCerebellumChemicalsClinicalClustered Regularly Interspaced Short Palindromic RepeatsDNADNA FoldingDNA RepairDataDependenceDependovirusDiseaseEmbryoEthylnitrosoureaFibroblastsFutureG-QuartetsGDF8 geneGaitGene ExpressionGenesGeneticGenetic TranscriptionGenomicsGoalsHealthHippocampus (Brain)HumanImpairmentInjectionsInvestigationLaboratory miceLocomotionMediatingMediationMediator of activation proteinMessenger RNAMethodsMissionMotorMovementMusMuscular DystrophiesMutant Strains MiceMutateMutationNeocortexNervous system structureNeurologicOrganismOutcomeOutputPerformancePersonsPharmaceutical PreparationsPharmacologyPhenotypePopulationPredispositionProsencephalonPurkinje CellsRadiationRadiation Induced DNA DamageRegulationResistanceSpinal CordSpinal Muscular AtrophyStrokeSynapsesSynaptic TransmissionSystemTestingTherapeuticTranscriptTranscriptional RegulationUnited States National Institutes of HealthUp-RegulationVideo RecordingWorkantagonistbasebehavior testcancer typedisabilitydrug developmentexperiencefunctional gaingene productloss of functionloss of function mutationmalignant breast neoplasmmanmotor disordermotor impairmentmotor learningmotor recoverymutantnervous system disorderneurophysiologynoveloverexpressionprotein expressionscreeningstemstroke recoverysynaptic functiontranscriptometranscriptomicstreadmill
项目摘要
MECHANISMS OF MOTOR SUPERPERFORMANCE: ABSTRACT
Clinical experience and world population-level data indicate that most neurological disability stems from motor
dysfunction. Yet, spontaneous superperformer mutations occur in a variety of species including man,
illustrating that the intrinsic motor capacity of the organism can be augmented. We set out to identify similar
mutations by rotarod screening of 33,806 laboratory mice harboring chemically induced random mutations with
the goal of mechanistically explaining and, eventually, pharmacologically enabling the phenomenon of motor
superperformance. In this context, we have discovered that a mutation in an unsuspected gene, Rif1
(Replication Timing Regulatory Factor 1), confers supernormal motor ability. Using clustered regularly
interspaced short palindromic repeats (CRISPR) Rif1-mutant mice, we have determined that: 1) mutant
superperformance is a selective phenotype, with distinct changes in motor features quantifiable by our novel
analysis method, but no other effects upon rigorous behavioral testing, and 2) the mutation also leads to
accelerated motor recovery from stroke. The superperformance mechanism, however, is unknown: although
Rif1 participates in DNA repair and in transcriptional regulation via G4 folded DNA structural stabilization, little
is known about its function in the nervous system. There is precedent that DNA repair may be associated to
synaptic transmission strength, while DNA G4 regulation could enhance the transcription of genes active in the
motor system. We have refined this hypothetical framework by identifying several consequences of the Rif1
mutation: a) Increased cerebellar Purkinje cell firing regularity and local field potential changes in the non-
moving mouse, which can influence movement precision, with change of these neurophysiological parameters
upon locomotion on a treadmill; b) Increased resistance to DNA-damaging radiation; c) Increased resistance to
G4 stabilization; d) Overexpression of a fraction of the cerebellar (but not forebrain or spinal cord) synaptic
transcriptome including potential Rif1 mutation mediators such as Kcnma1, Kif5c and Nab2; e) These
transcripts may be relevant to the phenotype because we show that loss of function mutations in them degrade
motor performance, whereas f) Cerebellar injection of adenovirus-containing Nab2 induces superperformance.
This proposal unifies this body of work by postulating that the Rif1 mutation modifies DNA repair and/or G4
DNA folding resulting in upregulation of synaptic transcripts, with either one or both mechanisms augmenting
the precision of cerebellar synapse activity relevant to movement control. To this effect, we will conduct
neurophysiological studies, determine the transcriptome in single cells, alter Kcnma1, Kif5c and Nab2
expression, and investigate DNA repair and DNA G4 regulation to test which of these mechanisms enable the
superperformance phenotype. Our goal is to initiate and steer the mechanistic investigation (by us or any
others) of Rif1 in the brain for ultimate therapeutic gain if appropriate.
运动超性能的机制:摘要
临床经验和世界人口水平的数据表明,大多数神经功能障碍源于运动
功能障碍。然而,自发的超级突变发生在包括人类在内的多种物种中,
说明有机体的内在运动能力可以增强。我们开始寻找类似的
通过转棒筛选 33,806 只携带化学诱导随机突变的实验室小鼠,进行突变
目标是从机械上解释并最终从药理学上实现运动现象
超强表现。在这种情况下,我们发现了一个未被怀疑的基因 Rif1 的突变
(复制计时调节因子1),赋予超常的运动能力。定期使用集群
间隔短回文重复序列 (CRISPR) Rif1 突变小鼠,我们确定:1) 突变体
超级表现是一种选择性表型,运动特征的明显变化可以通过我们的小说量化
分析方法,但对严格的行为测试没有其他影响,并且2)突变也会导致
加速中风后的运动恢复。然而,超性能机制尚不清楚:尽管
Rif1 通过 G4 折叠 DNA 结构稳定参与 DNA 修复和转录调控,很少
已知其在神经系统中的功能。有先例表明 DNA 修复可能与
突触传递强度,而 DNA G4 调节可以增强突触中活跃基因的转录
电机系统。我们通过确定 Rif1 的几个后果完善了这个假设框架
突变:a)增加小脑浦肯野细胞放电规律和非非局部场电位变化
移动鼠标,随着这些神经生理参数的变化,会影响运动精度
在跑步机上运动时; b) 增强对 DNA 损伤性辐射的抵抗力; c) 增加抵抗力
G4稳定; d) 小脑(但不是前脑或脊髓)突触部分的过度表达
转录组,包括潜在的 Rif1 突变介质,例如 Kcnma1、Kif5c 和 Nab2; e) 这些
转录本可能与表型相关,因为我们发现它们的功能缺失突变会降解
运动表现,而 f) 小脑注射含有腺病毒的 Nab2 可诱导超强表现。
该提案通过假设 Rif1 突变修改 DNA 修复和/或 G4 来统一这一工作主体
DNA 折叠导致突触转录本上调,其中一种或两种机制都会增强
与运动控制相关的小脑突触活动的精度。为此,我们将进行
神经生理学研究,确定单细胞中的转录组,改变 Kcnma1、Kif5c 和 Nab2
表达,并研究 DNA 修复和 DNA G4 调节,以测试这些机制中的哪一个能够实现
超性能表型。我们的目标是发起并指导机械调查(由我们或任何机构进行)
如果合适的话,大脑中的 Rif1 可以获得最终的治疗效果。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Genetic influences on motor learning and superperformance mutants revealed by random mutational survey of mouse locomotion.
通过对小鼠运动的随机突变调查揭示了遗传对运动学习和超性能突变体的影响。
- DOI:10.1101/2023.06.28.546756
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Jakkamsetti,Vikram;Ma,Qian;Angulo,Gustavo;Scudder,William;Beutler,Bruce;Pascual,JuanM
- 通讯作者:Pascual,JuanM
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Juan M. Pascual其他文献
Charcot-Marie-Tooth Disease
- DOI:
10.1017/9781107323704.088 - 发表时间:
2017 - 期刊:
- 影响因子:0
- 作者:
Juan M. Pascual - 通讯作者:
Juan M. Pascual
Juan M. Pascual的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Juan M. Pascual', 18)}}的其他基金
Dietary treatment of Glut1 deficiency (G1D) - Revision - 1
Glut1 缺乏症 (G1D) 的饮食治疗 - 修订版 - 1
- 批准号:
10447556 - 财政年份:2021
- 资助金额:
$ 53.97万 - 项目类别:
Pyruvate dehydrogenase encephalopathy: mechanisms and therapy
丙酮酸脱氢酶脑病:机制和治疗
- 批准号:
10225409 - 财政年份:2017
- 资助金额:
$ 53.97万 - 项目类别:
Pyruvate dehydrogenase encephalopathy: mechanisms and therapy
丙酮酸脱氢酶脑病:机制和治疗
- 批准号:
10000180 - 财政年份:2017
- 资助金额:
$ 53.97万 - 项目类别:
Dietary treatment of Glucose Transporter Type 1 Deficiency (G1D)
1 型葡萄糖转运蛋白缺乏症 (G1D) 的饮食治疗
- 批准号:
9755514 - 财政年份:2016
- 资助金额:
$ 53.97万 - 项目类别:
Dietary treatment of Glucose Transporter Type 1 Deficiency (G1D)
1 型葡萄糖转运蛋白缺乏症 (G1D) 的饮食治疗
- 批准号:
9538850 - 财政年份:2016
- 资助金额:
$ 53.97万 - 项目类别:
相似国自然基金
基于供应链视角的动物源性食品中抗微生物药物耐药性传导机制及监管策略研究
- 批准号:72303209
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
热带森林土壤氮添加下微节肢动物对氮转化过程的调控
- 批准号:32360323
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
Slc39a13在哺乳动物铁代谢中的作用
- 批准号:32371226
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
乳酸介导的组蛋白乳酸化调控哺乳动物主要合子基因组激活的机制研究
- 批准号:82301880
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
早期环境暴露对儿童哮喘免疫保护的动物实验和机制研究
- 批准号:82300031
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
A novel therapeutic approach for Alzheimer Disease (AD)
阿尔茨海默病(AD)的新治疗方法
- 批准号:
10740016 - 财政年份:2023
- 资助金额:
$ 53.97万 - 项目类别:
Accumbal integration of brain wide glutamatergic inputs and their dysregulation by cocaine self-administration
全脑谷氨酸能输入的累积整合及其可卡因自我给药的失调
- 批准号:
10620183 - 财政年份:2022
- 资助金额:
$ 53.97万 - 项目类别:
Accumbal integration of brain wide glutamatergic inputs and their dysregulation by cocaine self-administration
全脑谷氨酸能输入的累积整合及其可卡因自我给药的失调
- 批准号:
10464292 - 财政年份:2022
- 资助金额:
$ 53.97万 - 项目类别:
Translational Study of Blast mTBI Effects on Locus Ceruleus-Cerebellar Network Structure and Function
母细胞 mTBI 对蓝斑-小脑网络结构和功能影响的转化研究
- 批准号:
10514609 - 财政年份:2020
- 资助金额:
$ 53.97万 - 项目类别:
Translational Study of Blast mTBI Effects on Locus Ceruleus-Cerebellar Network Structure and Function
母细胞 mTBI 对蓝斑-小脑网络结构和功能影响的转化研究
- 批准号:
10343746 - 财政年份:2020
- 资助金额:
$ 53.97万 - 项目类别: